Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (141-150 of 196) with videos related to

Pageof 20
Sort By:
Breast (Edinburgh, Scotland)|February 19, 2026
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancerTimothé Guinel, Amélie Lusque, Audrey Mailliez, et al.
Clinical Breast Cancer|October 4, 2025
Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database StudyKatia Mahiou, Claire Bonneau, Charles Coutant, et al.
British Journal of Cancer|October 7, 2022
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutationsWilliam Jacot, Amélie Lusque, Cécile Vicier, et al.
Breast (Edinburgh, Scotland)|May 26, 2026
Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger womenMathilde Mairé, Fanny Bouteiller, Camille Chakiba, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
The New England Journal of Medicine|September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerAditya Bardia, Xichun Hu, Rebecca Dent, et al.
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Oncotarget|October 19, 2018
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancerMathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Journal of Clinical Medicine|February 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry StudyKarl Bordeau, Morgan Michalet, Aïcha Keskes, et al.
Pageof 20

Showing results (141-150 of 196) with videos related to

Sort By:
Pageof 20
Breast (Edinburgh, Scotland)|February 19, 2026
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancerTimothé Guinel, Amélie Lusque, Audrey Mailliez, et al.
Clinical Breast Cancer|October 4, 2025
Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database StudyKatia Mahiou, Claire Bonneau, Charles Coutant, et al.
British Journal of Cancer|October 7, 2022
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutationsWilliam Jacot, Amélie Lusque, Cécile Vicier, et al.
Breast (Edinburgh, Scotland)|May 26, 2026
Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger womenMathilde Mairé, Fanny Bouteiller, Camille Chakiba, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
The New England Journal of Medicine|September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerAditya Bardia, Xichun Hu, Rebecca Dent, et al.
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.
Clinical Pharmacology and Therapeutics|February 21, 2019
Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Oncotarget|October 19, 2018
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancerMathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Journal of Clinical Medicine|February 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry StudyKarl Bordeau, Morgan Michalet, Aïcha Keskes, et al.
Pageof 20